CD19-targeted therapies have shown unprecedented efficacy, achieving up to 90% complete response (CR) rates in trials for B cell acute lymphoblastic leukemia (B-ALL)3,4 and B cell lymphomas5,6,7 and there are now four US Food and Drug Administration (FDA)-approved CAR-T cell products targeting CD19. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.